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Abstract 
Background:  
The amount of insulin needed to effectively treat T2DM effectively worldwide is 
unknown. It also remains unclear how alternative treatment algorithms would affect 
insulin use and T2DM complication rates, given insulin access. 
 
Methods: 
We developed a microsimulation of T2DM burden from 2018 to 2030 across 221 
countries using data from the International Diabetes Federation (IDF) for prevalence 
projections and from fourteen cohort studies representing >60% of the global T2DM 
population for haemoglobin A1c (A1c), treatment, and weight data. We estimated the 
number of people with T2DM expected to use insulin, international units (IU) required, 
and disability adjusted life years (DALYs) gained per year under alternative treatment 
algorithms targeting A1c from 6.5% to 8%, lower microvascular risk, or higher A1c for 
those >75 years old.  
 
Results: 
The number of people with T2DM worldwide was estimated to increase from 405.6 
million in 2018 to 510.8 million in 2030. Insulin use would increase from 516.1 million 
1000IU vials (95% CI: 409.0, 658.6 million) to 633.7 million per year (95% CI: 500.5, 
806.7 million) from 2018 to 2030. Without improved insulin access, 7.4% (95% CI: 
5.8%, 9.4%) of people with T2DM in 2030 would use insulin, increasing to 15.5% (95% 
CI: 12.0% to 20.3%) if insulin were widely accessible and prescribed to achieve a 
A1c<7% (53 mmol/mol). If A1c<7% was universally achieved, insulin would avert 
331,000 DALYs per year by 2030 (95% CI: 256,600, 437,100). DALYs averted would 
increase 14.9% with access to newer oral glycemic agents. DALYS averted would 
increase by 44.2% if targeting A1c of 8% (64 mmol/mol) among people >75 years old, 
due to less hypoglycaemia.  
 
Discussion: 
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The insulin required to treat T2DM is expected to increase by over 20% from 2018 to 
2030, and may avert more DALYs if A1c targets are higher for older adults. 
 
Funding: The Leona M. and Harry B. Helmsley Charitable Trust 
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Introduction 
The prevalence of diabetes worldwide has nearly quadrupled since 1980.1 Adult 
diabetes prevalence (both type 1 and type 2) reached 425 million people in 2017 (~ 1 in 
11 adults).2 Around 12% of overall global healthcare expenditures are spent on diabetes 
treatment.2 
Insulin is necessary for all people with type 1 diabetes mellitus (T1DM) and a 
subset of patients with T2DM to avoid morbidity and mortality from ketoacidosis or 
hyperosmolar hyperglycaemic states, and to reduce long-term microvascular 
complications. The use of insulin for T2DM is dependent on treatment algorithms, 
particularly the target level of haemoglobin A1c (A1c).3 Finding an optimal target that 
maximizes disability-adjusted life years (DALYs) gained, while minimizing disutility 
from insulin therapy (e.g., from hypoglycaemia) remains an important goal.4 Insulin 
treatment is relatively costly,5 with most insulin produced by three major manufacturers.2 
Hence, a prospective estimation of global insulin requirements and the DALYs averted 
by improving access may help plan what resources are required to deliver insulin. 
Complicating such estimations are the increasing numbers of people with T2DM, 
increasing survival of people with T2DM (which may increase insulin requirements), and 
increasing availability of newer oral diabetes treatments. 
Here, we sought to estimate global insulin utilization for T2DM by country and 
year, worldwide, from 2018 to 2030 and the potential impacts of altering insulin 
treatment algorithms on insulin use and diabetes-related burden of disease.  
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Methods 
 
 A microsimulation (Figure 1) was constructed to simulate the population of 
adults with T2DM within each of 221 countries and territories worldwide to estimate the 
number of adults utilizing insulin, and to estimate the international units (IU) of insulin 
used under alternative treatment algorithms. IDF estimates for T2DM prevalence were 
multiplied by IDF estimates of the proportion of people diagnosed and then by the 
number estimated to need insulin (Appendix Table 1). The proportion estimated to need 
insulin was calculated in two ways, detailed below: (i) an approach using current 
estimates of insulin treatment from cohort studies; and (ii) an approach based on 
theoretical comprehensive insulin access (Table 1). In both cases, we used weight-based 
dosing and varied the A1c treatment target, then used the RECODe equations6,7 to 
estimate the DALYs averted from microvascular complications by insulin treatment, and 
a new risk equation to estimate the DALYs caused by hypoglycaemia events requiring 
medical attention (Appendix Table 2).  
 
Type 2 diabetes prevalence estimation 
Diabetes prevalence (both diagnosed and undiagnosed)  among adults in each 
country and year in the simulation was taken from projections made by the International 
Diabetes Federation (IDF) for the period 2018-2030.2 The IDF prevalence estimates were 
based on a regression model using data from a systematic review of literature for the 
individual country or nearest neighbourhood; the reviewed data were used by the IDF to 
generate smoothed sex- and age-specific prevalence estimates for adults 20–79 years old, 
which were projected by the IDF into the future using UN population projections and 
assuming that the age- and sex-specific prevalence of diabetes would increase linearly 
with urbanization.8 This conservative assumption produces a lower-bound estimate of 
future diabetes prevalence. Confidence intervals were constructed by the IDF by 
bootstrapping across study prevalence estimates in the systematic review, for which one 
study was removed from the data pool at a time. The prevalence estimates were for 
overall diabetes; based on a recent systematic review and projections, we estimated that 
96.5% of total diabetes among adults could be attributed to T2DM9 (varied in uncertainty 
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analyses to the range 92% to 99%). The estimate was based on a modelling exercise with 
extrapolation of ratios of incidence of T1DM in children to adults from available data 
applied to country-specific childhood T1DM incidence estimates.9 
 
Insulin needs estimate 
We undertook two parallel approaches to estimating the number of people 
utilizing insulin within each simulated country: (i) an approach accounting for 
demographic change but unchanged insulin access, which applied estimated proportions 
of people with T2DM currently treated with insulin to the estimated numbers of people 
with diagnosed T2DM in the future, and (ii) an approach accounting for demographic 
change and comprehensive insulin access, which estimated how many more people 
would be treated if all those estimated to need treatment with insulin under different 
treatment scenarios were provided with insulin, following appropriate oral glycaemic 
therapy, and conditional on a given treatment target for glycaemic control. 
In the approach accounting for demographic change alone (with unchanged 
insulin treatment rates; Figure 1A), we multiplied the absolute number of people 
projected to have diagnosed T2DM in each year over the period 2018-2030 by the 
proportion of those people who are anticipated to be treated with insulin given current 
estimates of the proportion of people with T2DM who receive insulin treatment in each 
country.2,10 The number of units of insulin required among those treated with insulin 
followed current guidelines based on weight, using the distribution of body weight 
among those diagnosed with T2DM and treated with insulin from regional surveys 
(Table 1). The estimates of body weight-based dosing assumed that 75% of those treated 
with insulin require only basal insulin at a dosage of 0.4 IU/kg/day, while the remaining 
individuals would require multiple dose injection therapy totalling 0.6 IU/kg/day.11,12 In a 
sensitivity analysis, we tested alternative assumptions, using 70% and 80% for 
proportions of people treated with insulin who require only basal insulin. 
In the approach accounting for both demographic change and improved insulin 
access (Figure 1B), we estimated the additional insulin required for the population not 
currently having access. First, we estimated the proportion of people with T2DM not 
currently receiving insulin from the geographically-closest regional diabetes survey for 
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each simulated country population, concatenating multiple surveys by taking an average 
if more than one was available (after accounting for survey sample weights from each) 
for a given country and bootstrapping across all available estimates when a close regional 
survey was unavailable. Details of each survey are provided in the Table 1, with 
comprehensive citations in the Appendix. Missing data—specifically, missing A1c 
values, body weight values, and indicators of whether or not a person was treated with 
insulin—were imputed with chained equations assuming data were missing at random,13 
followed by repeated Monte Carlo sampling from uncertainty distributions from each 
input parameter performed to estimate uncertainty.  
Among those not yet on insulin, we estimated whether or not insulin would be 
necessary after maximum treatment with oral glycaemic agents to achieve a given target 
A1c level (detailed below). Following current World Health Organization (WHO) 
guidelines and the WHO Essential Medicines List,14,15 titration was simulated up from 
500 mg daily of metformin to 1000 mg twice daily of metformin, then if needed, further 
addition of 80 mg daily of gliclazide (a sulfonylurea), which could be titrated up to 160 
mg twice daily. We Monte Carlo sampled from the distributions of typical A1c 
reductions for the full dose of each drug (uniform distributions) from a prior meta-
analysis,16 with proportionate linear values for doses below the maximum, taking into 
account existing dosage levels among those already on oral agents. Those people still 
above the target A1c after maximum titration of oral agents were assumed to achieve the 
target A1c only by starting insulin (after discontinuing the sulfonylurea) and setting their 
insulin use based on their weight (sampling from the weight estimates from the closest 
regional survey), estimating that 75% of those treated with insulin require only basal 
insulin at a dosage of 0.4 IU/kg/day (varied from 70% to 80% in sensitivity analyses), 
while the remaining individuals would require multiple dose injection therapy totalling 
0.6 IU/kg/day.11,12Among the population already receiving insulin, we estimated total 
daily insulin needed using these same estimates of total units per kilogram required per 
day. 
Finally, we conducted a sensitivity analysis to estimate how much less insulin 
may be required if newer agents were more widely available (e.g., GLP-1 agonists, DPP-
4 inhibitors, and SGLT-2 inhibitors) and combined with metformin instead of combining 
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a sulfonylurea with metformin; we used the A1c reductions estimated in a recent meta-
analysis to estimate the A1c effects of these newer agents.17 
 
Treatment targets 
 For the scenario accounting for both demographic change and improved insulin 
access, we simulated five different treatment targets. Recognizing that some 
facilities lack A1c testing, we converted to the nearest average fasting plasma 
glucose (AFPG) target level.16 We used the 2018 American Diabetes Association 
treatment guidelines as a primary clinical reference.18 
 First, we set the target A1c to 7.0% (53 mmol/mol) for all diagnosed and treated 
persons (AFPG = 8.0 mmol/L). 
 Second, we reduced the target A1c to a low of 6.5% (48 mmol/mol; AFPG = 7.5 
mmol/L). 
Third, we increased the target A1c to a high of 8.0% (64 mmol/mol; AFPG = 9.2 
mmol/L). 
 Fourth, we simulated an age-based target, with persons <75 years old given an 
A1c target of 7% and those >75 years old given a target A1c of 8%.19,20 
 Fifth, we simulated a risk-based target, with persons having >5% risk over 10 
years of composite microvascular complications (renal failure/end-stage renal disease, 
severe vision loss <20/200 on a Snellen chart, or loss of pressure sensation by 
monofilament testing) estimated from the RECODe equations6,7 treated with insulin to an 
A1c of 7% or the A1c level that achieved an estimated risk <5% (whichever A1c was 
higher). The threshold was based on prior experiments for risk-based therapy.21 
 
Outcome 
 The primary outcome metric we estimated was the number of people with T2DM 
estimated to use insulin for each year in each country and each world region (using 
United Nations categorizations of countries into regions). 
The secondary outcome metric was the number of 10mL vials of U100 insulin 
(i.e., 1,000IU) used per year in the total population of each country and each world region 
for each year from 2018 to 2030. 
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 For the scenario accounting for both demographic change and improved insulin 
access, the additional outcome metric was the DALYs averted by achieving the insulin 
treatment levels simulated. We computed the DALYs averted from each of three 
microvascular complications (renal failure/end-stage renal disease, severe vision loss 
<20/200 on a Snellen chart, or loss of pressure sensation by monofilament testing) using 
the RECODe equations for baseline risk for each complication re-calibrated to global 
DALY estimates from the Global Burden of Disease Project,6,7,22 the relative risk 
reduction conditional on A1c reduction for each complication from a prior systematic 
review,23 and the disability weights provided by a prior international survey (Appendix 
Table 3).24 We also computed the increase in DALYs due to: (i) the disutility of daily 
finger stick glucose monitoring; (ii) disutility from injection therapy, and (iii) disutility 
due to hypoglycaemia requiring hospitalization, emergency care, or other external 
medical assistance due to severe cognitive impairment, based on a risk equation to 
estimate the frequency of hypoglycaemia (Appendix Table 3). The hypoglycaemia risk 
equation was based on individual participant data from the ACCORD trial, and was a 
multivariable equation incorporating demographics, insulin units used, and related 
treatment covariates (Appendix Table 2). DALYs were computed at a standard 3% 
annual discount rate, integrated over the full life-course of all simulated individuals. 
 Outcomes were computed up to the year 2030, and additionally for the midpoint 
year of analysis (2024) for comparison. 
All estimates were performed in R (v. 3.4, R Foundation for Statistical 
Computing, Vienna), using the code deposited at 
https://github.com/sanjaybasu/insulinestimates for reproducibility.  
Page 9 of 30 
Results 
 First, we simulated the approach accounting for demographic change alone (with 
unchanged insulin access. The number of people projected to have T2DM over the period 
2018-2030 based on IDF estimates2 were 405.6 million in 2018 (95% CI: 315.3, 533.7 
million) and 510.8 million in 2030 (95% CI: 395.9, 674.3 million). The estimated number 
of people with T2DM in each country was typically proportional to population size, with 
the largest absolute number in 2018 residing in China (111.9 million; 95% CI: 97.1, 
146.3 million; 7.9% prevalence) and India (72.5 million; 95% CI: 52.8, 91.9 million; 
5.4% prevalence), followed by the United States, which had a higher prevalence (29.3 
million; 95% CI: 26.7, 31.7 million; 9.0% prevalence). Projections for the year 2030 by 
the IDF2 were proportional to anticipated population growth, aging, and urbanization in 
less developed countries, with the largest absolute numbers of people with T2DM 
projected to be in China (130.2 million; 95% CI: 113.4, 163.3 million; 9.0% prevalence), 
India (98.0 million; 95% CI: 73.7, 122.9 million; 6.5% prevalence), then the United 
States (31.8 million; 95% CI: 28.7, 34.5 million; 9.0% prevalence). When we combined 
data on the number of people with T2DM with the proportions diagnosed and treated 
with insulin,2,10 we estimated that insulin utilization would increase from 516.1 million 
1000-unit vials (95% CI: 409.0, 658.6 million) to 633.7 million vials per year (95% CI: 
500.5, 806.7 million) between 2018 and 2030. The number of vials utilized decreased or 
increased by 2% if the proportion of people treated with basal insulin only decreased 
from 75% to 70% or increased to 80%. The absolute number of people estimated to use 
insulin and the number of U100 insulin vials required would be lowest in the Oceanic 
region (4.2 million vials in 2030) and highest in Asia (321.6 million vials in 2030) due to 
population size (Table 2). In relative terms, the proportion of people with diagnosed 
T2DM utilizing insulin would be lowest in the African region due to low medication 
access and low prevalence of T2DM (1.8% of people with T2DM treated with insulin in 
2030) and highest in the Americas region in the context of greater insulin use and higher 
T2DM prevalence (13.6% of people with T2DM treated with insulin in 2030). 
 Second, we simulated both demographic change and improved insulin access. We 
estimated the proportion of people diagnosed with T2DM who could receive insulin after 
maximum oral therapy, if insulin were widely available and if providers aimed to achieve 
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a target A1c of 7% (Appendix Figure 1). The distribution of A1c among those with 
diagnosed T2DM (Table 1) had a global mean of 9.1% and 95% centiles extending from 
5.1% to 15.1%. The proportion of people with T2DM who we anticipated to use insulin 
increased from 7.4% (95% CI: 5.8%, 9.4%) to 15.5% (95% CI: 12.0% to 20.3%), on 
average, when changing from the scenario assuming persistence of current insulin access 
levels, to the scenario assuming comprehensive insulin access (Table 2). The greatest 
relative increase in number of people anticipated to use insulin between the two scenarios 
would be in the African region (7.1-fold increase from 718,800 if insulin access were at 
current levels to 5,119,900 under universal access), while the greatest absolute increase 
would be in the Asian region (+26.5 million people utilizing insulin from 21.1 million if 
insulin access were at current levels to 47.6 million under universal access). The ratio of 
actual utilization (given current insulin access levels) to estimated utilization (given 
comprehensive insulin access) varied from 0.14 in Africa to 0.71 in the Americas and 
was 0.48 worldwide. 
 We next estimated the net number of DALYs averted as a composite measure, 
accounting for the DALYs averted with comprehensive insulin access by preventing 
microvascular complications and subtracting the DALYs caused by insulin-related 
hypoglycemia and treatment-related inconvenience. When aiming for a treatment target 
of A1c of 7%, we estimated that comprehensive access to insulin would avert 263,000 
DALYs in the year 2018, increasing to 331,000 in the year 2030, with 65% of the 
DALYs averted in Asia alone (Table 2). On average, individuals reduced their composite 
lifetime risk of microvascular complications (renal failure, severe vision loss, and 
pressure sensation loss) from 17.4% to 15.9%, but increased their average lifetime risk of 
hypoglycaemia requiring medical attention from 11.9% to 20.0%. Nevertheless, due to 
the greater disutility of microvascular complications than of hypoglycaemia, overall net 
DALYs were averted through insulin treatment over the life-course, after accounting for 
the delayed onset of microvascular disease and a 3% annual discount rate on disutility 
over time. 
 Changing the target A1c produced a proportional change in the number of people 
estimated to use insulin, and in the absolute amount of insulin estimated to be required, 
though with overlapping confidence intervals based on Monte Carlo sampling (Figure 2). 
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A strict glycaemic control target of A1c = 6.5% increased the global number of people 
required to be on insulin, and the amount of insulin required, by 38.9% as compared to 
targeting A1c = 7%; conversely, a more liberal target of A1c = 8% reduced the global 
number of people required to be on insulin, and the amount of insulin required, by 45.0%. 
The overall net DALYs averted was related in a complex way to treatment targets 
(Figure 2C). In particular, targets of A1c = 6.5% or 7% had lower numbers of net 
DALYs averted than a target of 8%, as the lower levels of targeting increased DALYs 
caused by hypoglycaemia (see Figure 2D). The highest net DALYs averted was when 
targeting A1c = 7% for people <75 years old and 8% for people >75 years old, because 
this target helped avoid hypoglycaemic events that were concentrated primarily among 
older adults (Figure 2C). This age-stratified cut-off had 44.2% higher net DALYs 
averted than the universal target of 7%. Additional analyses in which the target A1c was 
risk-based (target of <5% for composite microvascular risk) was similar to the target A1c 
= 8% scenario (Figure 2C). Net DALYS averted for the midpoint year of 2024 were 
lower (by ~10%) than for the final year 2030, because of lower rates of diagnosis and 
lower total numbers of people with T2DM in 2024 than in 2030 (Appendix Figure 2). 
Finally, we conducted sensitivity analyses to estimate how much less insulin may 
be used if three types of newer agents were more widely available (GLP-1 agonists, DPP-
4 inhibitors, and SGLT-2 inhibitors) and combined with metformin instead of combining 
a sulfonylurea with metformin. The absolute number of people requiring insulin, and the 
units of insulin, did not change meaningfully given the non-significant difference from 
sulfonylurea in A1c reduction.17 However, the rate of hypoglycaemia was reduced due to 
avoidance of sulfonylurea treatment, and this increased the absolute net DALYs averted 
by 14.9%. The relative amount of net DALYs averted through each treatment target were 
not affected.  
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Discussion 
We estimated global insulin utilization for T2DM by country and year, 
worldwide, from 2018 to 2030. We observed several major findings in the course of our 
estimation. First, we observed that current levels of insulin access are not only inadequate 
relative to projected need, but are disproportionately inadequate in the African, Asian, 
and Oceanic regions. The regions projected to increase insulin utilization most if access 
were improved were the African region in relative terms, and the Asian region in absolute 
terms. The finding that Africa has the largest relative unmet insulin need also highlights 
the importance of availability and affordability improvements to the insulin market. Asia 
would similarly be expected to use the most insulin whether or not insulin access 
improved. Second, we observed that the DALYs averted through insulin therapy would 
be highest if targeting A1c levels of 7% for younger adults (<75 years old) and 8% for 
those of older age, to balance the risk of hypoglycaemia against the benefit of longer-
term reduced microvascular disease (though with overlapping confidence intervals 
between the alternative approaches simulated). The incremental reduction in 
microvascular risk by further lowering the A1c target was not outweighed by the increase 
in serious hypoglycaemia risk. We found that—for the overall population as a whole—
using more liberal target A1c of 8% used half as much insulin with only a 20% decline in 
DALYs saved. In comparison, intensive treatment to a goal A1c of 6.5% dramatically 
increased insulin use while increasing diabetes-related harms. Finally, we found that such 
insulin needs would be unlikely to be affected by expanded access to newer oral diabetes 
drugs, as such medicines are generally not more potent than existing drugs in reducing 
A1c;17 however, such drugs may substantially lower the risk of hypoglycaemia and 
thereby improve DALYs averted through therapy, though their cost may preclude their 
use in many situations.  
Several key assumptions should be noted. First, the projections of T2DM 
prevalence from the IDF are based on population projections and the existing 
relationships between age, sex, urbanization and diabetes prevalence. As dietary and 
physical activity environments can change in both obesogenic and disease-reducing 
ways, the IDF projections may be either optimistic or pessimistic in unpredictable 
directions. Second, the RECODE equations we used were previously derived and 
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validated from U.S. samples, though we recalibrated the baseline hazard rates of events 
here to match Global Burden of Disease estimates.6,7,22 The use of these equations 
assumes that the relationship between underlying demographics (age, sex), biomarkers 
(blood pressure, A1c) and complications is consistent across countries, which may 
neglect some ethnic variations. Third, our estimates of hypoglycaemia risk are based on a 
logistic regression (incorporating risk factors such as age and insulin dosage) internally 
cross-validated in the ACCORD study sample, but not externally validated in another 
study sample. Fourth, we used the distributions of body weight, A1c and insulin 
utilization from available cohort studies in the absence of comprehensive longitudinal 
data of high quality across all countries. Additionally, we lacked sufficient data to 
estimate the degree to which different oral antidiabetic agents have different durability in 
maintaining A1c reductions over time.25–27  
 Future research into the issues raised here should consider how key barriers to 
availability and accessibility of diagnosis and therapy in the African region in particular 
may be overcome,28 and how Ministries of Health can best prepare for the anticipated 
large increase in insulin utilization needs in the coming years.  
 Prior to such research, our study reveals that insulin utilization is likely to rise 
particularly in Asia, and that targeting a moderate threshold for control—potentially 
based in part on age as a proxy for life expectancy and co-morbidities—may help balance 
the risks of insulin therapy with longer-term microvascular benefit. 
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Putting research in context 
Evidence before this study 
We conducted a PubMed search for articles with the keywords “insulin 
utilization” and “type 2 diabetes” from 2008 through August 2018. We found seven prior 
papers on the topic. Three papers reviewed the insulin dosing needs and effectiveness of 
insulin for people with T2DM when using basal insulin with or without other antidiabetic 
medications. Two articles examined the budgetary and cost impact of basal insulin 
utilization in the United States population. The remaining two papers estimated the low 
rates of access to insulin and challenges to access in East and South Asia.  
 
Added value of this study 
By comparison to the existing literature, our current study offers a direct estimate 
of the anticipated global use of insulin among persons with T2DM, using data from large 
representative cohort studies, and directly compares the implications of alternative 
treatment targets for reducing the burden of T2DM complications.   
 
Implications of all the available evidence 
 The overall evidence suggests that the number of people requiring insulin and the 
amount of insulin required to treat T2DM is expected to increase and require substantial 
improvements to access in low- and middle-income countries. 
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Tables and Figures 
 
Table 1: Input cohort data for estimating reduction in haemoglobin A1c necessary to 
achieve treatment targets, and baseline proportion of people with T2DM treated with 
insulin, among those diagnosed with T2DM. References for each cohort dataset are 
provided in the Appendix. 
 
Dataset N with diabetes 
by prior 
diagnosis or 
labs 
Years A1c, mean 
(95% 
centiles), %  
% treated with 
insulin, among 
those diagnosed 
Weight, mean 
(95% 
centiles), kg. 
U.S. National Health and Nutrition 
Examination Survey 
1,441 2009-
2014 
7.4 (5.2, 
12.2) 
22.2 89.5 (53.7, 
148.2) 
U.S. National Institutes of Health 
Global Health Centers of 
Excellence surveys from South 
Africa 
1,842 2012 9.1 (5.4, 
14.6) 
- 83.0 (51.0, 
125.0) 
U.S. National Institutes of Health 
Global Health Centers of 
Excellence surveys from India 
1,605 2015 8.7 (5.5, 
13.4) 
- 67.9 (43.0, 
98.2) 
South Africa National Health and 
Nutrition Examination Survey 
747 2012 7.7 (5.4, 
12.8) 
4.4 78.0 (44.0, 
116.6) 
U.K. National Health Service 
National Diabetes Audit 
16,585 2016-
2017 
7.3 (5.1, 
12.1) 
12.5 80.3 (48.1, 
133.0) 
Indian Jaipur Diabetes Registry 8,699 2014 9.0 (6.3, 
14.8) 
9.1 60.4 (30.6, 
101.2) 
Swedish National Diabetes 
Register 
17,827 2016 8.4 (6.1, 
10.1) 
11.7 75.6 (48.5, 
102.7) 
Danish Adult Diabetes Registry 11,205 2014-
2015 
7.7 (5.4, 
12.7) 
15.8 70.9 (33.9, 
123.5) 
Turkish Nationwide survey of 
Glycemic and Other Metabolic 
Parameters of Patients 
with Diabetes Mellitus 
4,672 2017 7.5 (5.3, 
12.4) 
9.6 84.7 (52.2, 
117.2) 
China Health and Nutrition Study 1,422 1999-
2015 
7.8 (5.2, 
12.7) 
18.3 65.5 (45.2, 
90.0) 
DiabCare study of the Philippines 770 2008 8.0 (5.6, 
13.2) 
25.0 58.5 (36.2, 
85.9) 
Japan National Health and 
Nutrition Survey 
1,434 2016 7.2 (5.0, 
11.8) 
7.0 59.5 (32.2, 
90.4) 
Korea National Health and 
Nutrition Examination Survey 
1,341 2010-
2012 
8.2 (5.7, 
13.5) 
3.0 66.0 (38.5, 
93.7) 
Joint Asia Diabetes Evaluation 28,111 2007- 7.7 (5.4, 21.0 76.8 (58.4, 
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Registry 2012 12.7) 90.0) 
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Table 2:  
Outcome measures by world region, when the treatment target was set to haemoglobin 
A1c equal to 7%. T2DM: type 2 diabetes mellitus; CI: confidence interval.  
 
Metric Region Demographic change only Demographic change and 
comprehensive access to insulin  
Outcome, 2018 
(95% CI) 
Outcome, 2030 
(95% CI) 
Outcome, 2018 
(95% CI) 
Outcome, 2030 
(95% CI) 
People with T2DM 
utilizing insulin, No. 
(95% CI), % of 
people with T2DM 
Africa 502,647 (288,690, 
798,943), 1.8% 
718,802 (421,154, 
1,226,177), 1.8% 
3,580,238 
(2,056,273, 
5,690,693), 12.7% 
5,119,862 
(2,999,782, 
8,733,785), 12.5% 
Americas 9,695,648 
(7,665,389, 
11,537,007), 
13.7% 
12,235,005 
(9,630,417, 
14,632,677), 
13.6% 
13,687,550 
(10,821,390, 
16,287,035), 
19.3% 
17,272,413 
(13,595,462, 
20,657,257), 19.2% 
Asia 16,684,889 
(13,361,708, 
21,796,053), 
6.4% 
21,093,158 
(16,923,703, 
27,319,674), 
6.4% 
37,619,272 
(30,126,523, 
49,143,366), 
14.4% 
47,558,556 
(38,157,723, 
61,597,425), 14.3% 
Europe 3,162,812 
(2,385,353, 
4,469,907), 7.5% 
3,372,393 
(2,469,168, 
4,761,120), 7.5% 
7,993,805 
(6,028,827, 
11,297,404), 
19.0% 
8,523,506 
(6,240,663, 
12,033,426), 18.9% 
Oceania 183,439 (123,104, 
240,038), 7.8% 
218,324 (155,957, 
282,674), 7.7% 
435,532 (292,280, 
569,911), 18.5% 
518,356 (370,282, 
671,140), 18.3% 
Global 
Total 
30,229,435 
(23,824,244, 
38,841,948), 
7.5% 
37,637,682 
(29,600,399, 
48,222,322), 
7.4% 
63,316,397 
(49,325,293, 
82,988,409), 
15.6% 
78,992,693 
(61,363,912, 
103,693,033), 
15.5% 
U100 insulin vials 
(1000 units each) 
used per year, No. 
(95% CI)  
Africa 8,624,782 
(4,912,881, 
13,373,521) 
12,305,853 
(7,090,162, 
20,337,229) 
61,432,374 
(34,993,342, 
95,256,567) 
87,651,814 
(50,501,623, 
144,857,489) 
Americas 185,734,884 
(148,644,626, 
218,458,562) 
229,389,030 
(182,349,618, 
271,640,903) 
262,205,836 
(209,844,740, 
308,402,539) 
323,833,311 
(257,426,785, 
383,481,167) 
Asia 255,959,077 
(206,143,552, 
334,166,375) 
321,604,383 
(259,506,395, 
415,709,828) 
577,108,650 
(464,790,030, 
753,441,950) 
725,118,538 
(585,106,758, 
937,297,246) 
Europe 62,218,758 
(46,900,997, 
88,025,335) 
66,228,854 
(48,525,714, 
93,594,458) 
157,253,927 
(118,539,269, 
222,478,398) 
167,389,188 
(122,645,636, 
236,554,000) 
Oceania 3,517,167 
(2,388,704, 
4,588,735) 
4,170,065 
(2,989,682, 
5,383,238) 
8,350,661 
(5,671,400, 
10,894,840) 
9,900,809 
(7,098,276, 
12,781,196) 
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Global 
Total 
516,054,668 
(408,990,760, 
658,612,528) 
633,698,185 
(500,461,571, 
806,665,656) 
1,066,351,448 
(833,838,781, 
1,390,474,294) 
1,313,893,660 
(1,022,779,078, 
1,714,971,098) 
DALYs averted by 
insulin treatment, 
No. (95% CI) 
Africa - - 18,321 (10,517, 
29,451) 
26,585 (15,532, 
45,613) 
Americas - - 46,019 (36,477, 
54,594) 
58,216 (45,933, 
69,554) 
Asia - - 169,807 (135,827, 
221,226) 
215,179 (172,646, 
277,939) 
Europe - - 27,208 (20,524, 
38,645) 
29,282 (21,192, 
41,539) 
Oceania - - 1,529 (999, 2,026) 1,839 (1,298, 2,408) 
Global 
Total 
  262,884 (204,344, 
345,942) 
331,101 (256,601, 
437,053) 
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Figure 1: Study flow diagram. Each cell describes a key input data (with source 
parenthetically) or outcome estimate (with estimation approach parenthetically). Two 
approaches were used to estimate the outcomes: (i) an approach incorporating 
demographic change only (left side of dashed line) and (ii) an approach incorporating 
both demographic change and improved insulin access (right side of dashed line).  
Legend: T2DM: type 2 diabetes mellitus. IDF: International Diabetes Federation. 
 
Page 24 of 30 
Page 25 of 30 
 Figure 2: Variations in insulin treatment and DALYs averted under alternative treatment 
targets in the year 2030. All estimates are made with the approach defined in the Methods 
section that accounted for both demographic change and increased insulin access. The 
height of the bars reflects the mean, and error bars reflect 95% confidence intervals. 
Legend: Base case: target A1c of 7.0% (53 mmol/mol) for all diagnosed and treated 
persons (AFPG = 8.0 mmol/L); intensive: target A1c of 6.5% (48 mmol/mol; AFPG = 7.5 
mmol/L); liberal: target A1c of 8.0% (64 mmol/mol; AFPG = 9.2 mmol/L); age-tailored: 
with persons <75 years old target A1c of 7% and for those >75 years old target A1c of 
8%;19,20 risk-based: with persons having >5% risk over 10 years of composite 
microvascular complications (renal failure/end-stage renal disease, severe vision loss 
<20/200 on a Snellen chart, or loss of pressure sensation by monofilament testing) 
estimated from the RECODe equations6,7 target A1c of 7% or the A1c level that achieved 
an estimated risk <5% (whichever A1c was higher).21 Numerical values corresponding to 
these figures are provided in Appendix Table 4. 
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 (A) People with type 2 diabetes mellitus estimated to use insulin 
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(B) Number of U100 insulin vials (1000 units each) used per year 
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(C) Net DALYs averted by insulin treatment 
 
Page 29 of 30 
(D) Ratio of DALYS averted by prevention of microvascular events with insulin 
treatment, versus from DALYs induced by insulin treatment (including hypoglycaemia 
requiring medication attention, daily finger sticks, and injections), worldwide. 
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